Letters

Throughout the year, the AHA comments on a vast number of proposed and interim final rules put forth by the federal regulatory agencies. In addition, AHA communicates with federal legislators to convey the hospital field's position on potential legislative changes that would impact patients and patient care. Below are the most recent letters from the AHA to these bodies.

Latest

AHA provides input on the Centers for Medicare & Medicaid Services’ Request for Information regarding electronic prescribing of controlled substances (EPCS).
The American Hospital Association asks the Secretary of Health and Human Services (HHS) to reinstate the COVID-19 Provider Relief Fund (PRF) reporting requirements outlined in your June 19 frequently asked question that defined both expenses and lost revenues attributable to COVID-19.
Nearly 30 representatives encourage House leaders to modify in the next COVID-19 response package impending thresholds for qualifying participants in Advanced Alternative Payment Models, which they said threaten to “derail” the movement to value-based care under the Medicare Access and CHIP Reauthorization Act.
AHA's input on the Health Resources and Services Administration’s (HRSA) Health Professional Shortage Area (HPSA) Scoring Criteria request for information (RFI).
The AHA requests that the Department of Health and Human Services revise certain FAQs that place problematic restrictions on the use of some CARES Act Provider Relief Fund dollars.
AHA comments on the National Academies of Sciences, Engineering and Medicine’s Discussion Draft of the Preliminary Framework for Equitable Allocation of COVID-19 Vaccine.
AHA to HHS again expressing concern with recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to our hospital members.
AHA urges the Centers for Medicare & Medicaid Services (CMS) to withdraw the condition of participation that hospitals report daily COVID-19 data.
Letter from AHA to President Donald Trump urging additional support for rural hospitals and health systems.
On behalf of the nation’s 340B hospitals, AHA, others urge HHS to protect vulnerable communities from actions taken by five of the nation’s largest pharmaceutical manufacturers that undermine access to critical drugs and other health care services.